| Private Placement / Financing Transactions
Mediar Therapeutics: The company raised $37.8 million of Series B venture funding from undisclosed investors on December 23, 2025, putting the company’s pre-money valuation at $140 million. The company is a developer of innovative fibrosis treatment intended for halting and reversing fibrotic activity.
Myrtelle: The company raised $30.5 million of venture funding from undisclosed investors on December 23, 2025. The company is an operator of a gene therapy business intended to offer innovative clinical trials for the treatment of the rare monogenic disorder.
Auron Therapeutics: The company raised $27.3 million of Series B venture funding in a deal led by DCVC on December 23, 2025. Eli Lilly, BrightEdge, Apollo Health Ventures, Qiming Venture Partners USA, Polaris Partners, Arkin Bio Ventures, and Mubadala Capital also participated in the round. The company is an operator of a biotechnology business intended to research and develop products focusing on the immunology and oncology medical fields.
Vyriad: The company raised $25 million of Series B venture funding in a deal led by Stine Seed Company on December 23, 2025, putting the company’s pre-money valuation at $194 million. The company is a developer of targeted genetic therapies using engineered viruses, viral vectors, and viral envelope glycoproteins to deliver genes directly to targeted cells.
Flywheel: The company raised $18.6 million of venture funding from undisclosed investors on December 31, 2025. The company is a developer of a cloud-based research data management platform designed to accelerate biomedical research and collaboration.
Notable Systems: The company raised $18.1 million of Series B venture funding in a deal led by Harbert Growth Partners and Grotech Ventures on December 22, 2025, putting the company’s pre-money valuation at $24.9 million. FirstTracks Ventures also participated in the round. The company is a developer of intelligent document processing platforms that automate data extraction from clinical documents to digital systems.
Nacuity Pharmaceuticals: The company raised $12.9 million of venture funding in a deal led by Retinal Degeneration Fund and Foundation Fighting Blindness-National Neurovision Research Institute on December 29, 2025. The company is an operator of a biotechnology business intended to offer treatments for retinitis pigmentosa and other ophthalmological disorders.
Nature’s Toolbox: The company raised $9.9 million of venture funding from undisclosed investors on December 23, 2025. The company is a developer of scalable biomanufacturing platforms for sustainable production of biologics and cell therapies.
Igniton: The company raised $7.4 million of venture funding from undisclosed investors on December 29, 2025. The company is a producer of nootropic supplements for cognitive enhancement, memory support, longevity optimization, and sustained energy.
Hyku: The company raised $6.6 million of venture funding in the form of convertible debt from undisclosed investors on January 2, 2026. The company is a developer of small molecule therapeutics with novel mechanisms targeting protein drivers of disease progression.
SynDevRx: The company raised $6.4 million of Series C venture funding in the form of convertible debt from undisclosed investors on December 22, 2025. The company is a developer of therapeutic approaches designed to target the metabolic drivers and vascular factors that influence cancer progression.
Double Blind Bio: The company raised $5.6 million of venture funding from undisclosed investors on December 23, 2025. The company is a developer of a clinical trial AI assistance platform intended to source, engage and secure clinical trials.
GEn1E Lifesciences: The company raised $5.5 million of Series Prime venture funding from Advagen Holdings, Leblon Capital, and other undisclosed investors on December 23, 2025, putting the company’s pre-money valuation at $130 million. The company is a developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases.
Alume Biosciences: The company raised $5.3 million of Series C venture funding from undisclosed investors on December 31, 2025. The company is a developer of a nerve illumination technology designed to help doctors perform precision surgery.
Digital Health Strategies: The company raised $5.3 million of Series B venture funding from undisclosed investors on December 23, 2025, putting the company’s pre-money valuation at $25.7 million. The company is a developer of a healthcare customer relationship management platform designed to improve the patient experience.
KIVO: The company raised $5.1 million of venture funding from undisclosed investors on December 23, 2025. The company is a developer of a document management and collaboration platform designed to serve early-stage life science organizations.
Alpenglow Biosciences: The company raised $4.8 million of venture funding in the form of convertible debt from undisclosed investors on December 31, 2025. The company is a developer of a microscopy imaging system designed to analyze images of complex and morphological structures of tissue samples.
Kimialys: The company raised EUR 3.6 million of Series A venture funding in a deal led by Turenne Groupe on December 23, 2025. GO Capital, Angels Santé and other undisclosed investors also participated in the round. The company is a developer of customized biofunctionalized nanoparticles and surfaces designed to improve the performance of in vitro diagnostics.
Navidence: The company raised $3 million of venture funding from Teamworthy Group and other undisclosed investors on December 29, 2025. The company is a developer of real-world evidence systems for data generation and analysis to support regulatory submissions.
CyGenica: The company raised an undisclosed amount of venture funding from 3iPartners in January 2026. The company is a developer of molecular drug delivery devices for intracellular delivery of anticancer drugs, antibiotics, and gene editing tools.
|
